DUPHALAC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Duphalac, and when can generic versions of Duphalac launch?
Duphalac is a drug marketed by Solvay and is included in one NDA.
The generic ingredient in DUPHALAC is lactulose. There are twenty drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the lactulose profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Duphalac
A generic version of DUPHALAC was approved as lactulose by HIKMA on July 3rd, 1995.
Summary for DUPHALAC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 28 |
Clinical Trials: | 4 |
Patent Applications: | 3,828 |
Formulation / Manufacturing: | see details |
DailyMed Link: | DUPHALAC at DailyMed |
Recent Clinical Trials for DUPHALAC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
RenJi Hospital | Phase 4 |
Bogomolets National Medical University | N/A |
Indian Council of Medical Research | Phase 2/Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for DUPHALAC
US Patents and Regulatory Information for DUPHALAC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Solvay | DUPHALAC | lactulose | SOLUTION;ORAL | 072372-001 | Mar 22, 1989 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |